Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the industrialized world. Prof. Hallek developed treatment approaches that have significantly improved the prognosis for CLL patients. He also established the German CLL Study Group (DCLLSG) in 1996 - one of the world's largest study group for this disease. Over 10,000 patients have been treated to date. The research results led to the approval of various new drugs.
Prof. Hallek joined the University Hospital Cologne in 2003 as Director of Dept. I for Internal Medicine and joined the Center for Molecular Medicine Cologne in 2005 . Shortly afterwards, he founded the Center for Integrated Oncology Cologne Bonn (CIO) and established it as one of the largest oncological centers of excellence in Germany.
He studied medicine in Regensburg, Munich and Paris. In the 1990s he worked for two years as postdoctoral student at the Dana-Farber-Cancer Institute at the Harvard Medical School in Boston. For his research, Prof. Hallek received numerous scientific awards, most recently the Paul Martini Prize in 2012. Prof. Hallek is a member of the National Academy of Sciences Leopoldina.
The German Cancer Award is awarded annually by the "Deutsche Krebsgesellschaft" and the "Deutsche Krebsstiftung" in equal parts for outstanding work in the German-speaking world:
https://www.krebsgesellschaft.de/deutsche-krebsgesellschaft/presse.html
http://www.deutsche-krebsstiftung.de/index.php
Modified press release from
Copyright ©
Prof. Dr. med. Thomas Benzing
Chair of the CMMC
